Not checkedNot checked for notices yet.
DRUG NEUROPROTECTION IN FULL-TERM NEWBORNS WITH SEVERE CEREBRAL ISCHEMIA
A. A. Zadvornov, A. V. Golomidov, E. V. Grigoriev
Вестник анестезиологии и реаниматологии · 2018
doi:10.21292/2078-5658-2016-13-3-51-62 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Severe cerebral ischemia of newborns remains to be the main cause of children disability and mortality and neuroprotection is the main way to reduce them. Therapeutic hypothermia being widely introduced into clinical practice nowadays has the number of limitations. It requires searching for effective pharmacological neuroprotection providing impact on numerous pathogenic mechanisms of neuronal damage. These promising neuroprotective agents include melatonin, erythropoietin, topiramate, cannabinoids, barbiturates and magnesium sulfate. Promising neuroprotection in newborns can include antenatal use in case of fetal distress or potentation and/or postponed use of therapeutic hypothermia with their post-natal administration. Data currently available from clinical studies do not allow recommending any of the above drugs for routine clinical use. However in future clinical studies now in progress will allow finding the effective neuroprotection and optimal mode for its use in newborns with severe cerebral ischemia.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.